Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

The aim of this study was to compare the metabolic outcomes, safety, and caregiver treatment satisfaction of basal-bolus multiple daily injection (MDI) therapy with mealtime insulin aspart (IAsp) or human insulin (HI) (both with basal NPH insulin), or of continuous subcutaneous infusion (CSII) with IAsp in preschool-age children with type 1 diabetes mellitus.

Who Took Part

The study group was 61 children.

The age groups tagged for this paper are young children and children, both men and women.

After a 3-week HI MDI run-in, 61 children <7 years old were randomized to IAsp MDI or HI MDI or allocated to IAsp CSII for 26 weeks.

Caregiver treatment satisfaction was evaluated using a World Health Organization questionnaire with 7-point scale answers.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

The methods mention a period of 3 weeks.

Safety evaluation included hypoglycemia and adverse events.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Glycated Hemoglobin, Hypoglycemic Agents, Insulin, Insulin Aspart, Patient Satisfaction and Surveys and Questionnaires.

What This Means in Plain Language

The paper is a randomized study of Insulin Aspart in 61 children over 3 weeks.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page.